Clinical trials: Post-Essential Thrombocythemia Myelofibrosis (Post-ET MF)
- Condition Post-Essential Thrombocythemia Myelofibrosis (Post-ET MF)
- Funder type Industry (pharma, biotech, devices)
Primary Myelofibrosis
A Study of Fedratinib in Japanese Subjects With DIPSS (Dynamic International Prognostic Scoring System)- Intermediate or High-risk Primary Myelofibrosis (PMF), Post-polycythemia Vera Myelofibrosis (Post-PV MF), or Post-essential Thrombocythemia Myelofibrosis (Post-ET MF)
The study will be conducted in compliance with the International Council for Harmonisation (ICH) of Technical Requirements for Registration of Pharmaceuticals for Human Use/Good Clinical Practice (GCP) and applicable regulatory…
- Trial name
- NCT04446650
- Testing
- Fedratinib
- Where
- 21 sites in Japan
- Volunteers
- 31 people
- Sponsor
- Bristol-Myers Squibb
Primary Myelofibrosis (PMF), Post-polycythemia Vera Myelofibrosis (Post-PV MF)
Study of Pelabresib add-on to Ruxolitinib in Japanese Adult Patients With Myelofibrosis
This Phase 1b, multicenter, open-label study aims to evaluate the safety, pharmacokinetics (PK), and preliminary efficacy of pelabresib as add-on to ruxolitinib in Japanese patients with myelofibrosis (MF).
- Conditions
- Primary Myelofibrosis (PMF), Post-polycythemia Vera Myelofibrosis (Post-PV MF), Post-essential Thrombocythemia Myelofibrosis (Post-ET MF)
- Trial name
- NCT07340138
- Testing
- Pelabresib, Ruxolitinib
- Where
- 3 sites in Japan
- Volunteers
- 3 people
- Sponsor
- Novartis Pharmaceuticals
Myelofibrosis
An Open-Label, Multicenter, Phase 1b/2 Study of the Safety and Efficacy of KRT-232 Combined With Ruxolitinib in Patients With Primary Myelofibrosis (PMF), Post-Polycythemia Vera MF (Post-PV-MF), Or Post-Essential Thrombocythemia MF (Post ET-MF) Who Have a Suboptimal Response to Ruxolitinib
This is a phase 1b/2 study of KRT-232 combined with ruxolitinib in subjects with MF who have a suboptimal response after at least 18 weeks of treatment with ruxolitinib.
- Trial name
- NCT04485260
- Testing
- KRT-232, Ruxolitinib
- Where
- 38 sites in United States, Australia and 7 more
- Volunteers
- 36 people
- Sponsor
- Kartos Therapeutics, Inc.
Myelofibrosis, Myelofibrosis Due to and Following Polycythemia Vera
Flonoltinib Maleate Oral Regimens in Patients With Myelofibrosis
The goal of this clinical trial is to learn which of three different doses of Flonoltinib Maleate taken by mouth daily works best to treat adult patients with myelofibrosis in whom the most common approved therapy has failed to…
- Conditions
- Myelofibrosis, Myelofibrosis Due to and Following Polycythemia Vera, Myelofibrosis Transformation in Essential Thrombocythemia, Myelofibrosis With High Molecular Risk Mutations
- Trial name
- FM-MF-02 (NCT07750574)
- Testing
- Flonoltinib Maleate orally
- Volunteers
- 105 people
- Sponsor
- Chengdu Zenitar Biomedical Technology Co., Ltd
Primary Myelofibrosis (MF), Post-Polycythemia Vera (PV) MF
Asian Phase II Study of INC424 in Patients With Primary Myelofibrosis (MF), Post-PV MF or Post-ET MF
The objective of this study was to determine the efficacy of INC424 as assessed by reduction in spleen volume in patients with primary myelofibrosis (MF), post-polycythemia vera (PV) MF, or post-essential thrombocythemia (ET) MF.
- Conditions
- Primary Myelofibrosis (MF), Post-Polycythemia Vera (PV) MF, Post-Essential Thrombocythemia (ET) MF
- Trial name
- NCT01392443
- Testing
- Ruxolitinib
- Where
- 26 sites in China, Japan and 2 more
- Volunteers
- 120 people
- Sponsor
- Novartis Pharmaceuticals
Primary Myelofibrosis (PMF), Post-polycythemia Vera Myelofibrosis(Post-PV MF)
Jaktinib for the Treatment of Ruxolitinib Intolerance of Myelofibrosis
This phase IIB, open-label, multicenter study evaluated the efficacy and safety of oral Jaktinib Hydrochloride Tablets in Intermediate-risk and High-risk Myelofibrosis and Previously Treated With Ruxolitinib.
- Conditions
- Primary Myelofibrosis (PMF), Post-polycythemia Vera Myelofibrosis(Post-PV MF), Post-essential Thrombocythemia Myelofibrosis(Post-ET MF)
- Trial name
- NCT04217993
- Testing
- Jaktinib hydrochloride tablets
- Where
- China
- Volunteers
- 51 people
- Sponsor
- Suzhou Zelgen Biopharmaceuticals Co.,Ltd
Primary Myelofibrosis
Extended Access of Momelotinib in Adults With Myelofibrosis
This is an extended-access, long-term safety study for participants with primary myelofibrosis (PMF), post-polycythemia vera myelofibrosis (post-PV MF), or post-essential thrombocythemia myelofibrosis (post-ET MF) who have not…
- Trial name
- NCT03441113
- Testing
- Momelotinib
- Where
- 112 sites in United States, Australia and 18 more
- Volunteers
- 237 people
- Sponsor
- GlaxoSmithKline
Primary Myelofibrosis, Thrombocytosis
A Phase Ib/II Dose-finding Study to Assess the Safety and Efficacy of LDE225 + INC424 in Patients With MF
The purpose of this phase Ib/II clinical trial was to: a) evaluate the safety of the co-administration of LDE225 and INC424 in myelofibrosis patients and establish a maximum tolerated dose and/or Recommended Phase II dose of the…
- Conditions
- Primary Myelofibrosis, Thrombocytosis, Essential Thrombocythemia, Polycythemia Vera
- Trial name
- NCT01787552
- Testing
- LDE225, INC424
- Where
- 18 sites in Australia, Belgium and 9 more
- Volunteers
- 50 people
- Sponsor
- Novartis Pharmaceuticals
Primary Myelofibrosis (PMF), Post-Polycythemia Vera MF (Post-PV-MF)
KRT-232 Versus Best Available Therapy for the Treatment of Subjects With Myelofibrosis Who Are Relapsed or Refractory to JAK Inhibitor Treatment
This study evaluates KRT-232, a novel oral small molecule inhibitor of MDM2, for the treatment of patients with myelofibrosis (MF) who no longer benefit from treatment with a JAK inhibitor.
- Conditions
- Primary Myelofibrosis (PMF), Post-Polycythemia Vera MF (Post-PV-MF), Post-Essential Thrombocythemia MF (Post-ET-MF)
- Trial name
- BOREAS (NCT03662126)
- Testing
- KRT-232, Best Available Therapy (BAT)
- Where
- 191 sites in United States, Argentina and 26 more
- Volunteers
- 385 people
- Sponsor
- Kartos Therapeutics, Inc.
Myelofibrosis
A Safety and Tolerability Study of Jaktinib
This research study is studying a drug called Jaktinib as a possible treatment for Myelofibrosis.
- Trial name
- NCT05279001
- Testing
- Jaktinib Hydrochloride Tablet
- Where
- United States
- Volunteers
- 26 people
- Sponsor
- Suzhou Zelgen Biopharmaceuticals Co.,Ltd
Myelofibrosis, Primary Myelofibrosis
Study of TL-895 Combined With Ruxolitinib in JAKi Treatment-Naïve MF Subjects and Subjects With MF Who Have a Suboptimal Response to Ruxolitinib
This study evaluates TL-895, a potent, orally-available and highly selective irreversible tyrosine kinase inhibitor for the treatment of Myelofibrosis.
- Conditions
- Myelofibrosis, Primary Myelofibrosis, Post-PV MF, Post-ET Myelofibrosis
- Trial name
- NCT05280509
- Testing
- TL-895, Ruxolitinib
- Where
- 19 sites in United States, France and 4 more
- Volunteers
- 70 people
- Sponsor
- Telios Pharma, Inc.
Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (Post-PV MF)
Assess the Safety, Tolerability Oral PU-H71 in Subjects Taking Ruxolitinib
This is a multicenter, Phase 1b study with dose escalation and expansion cohorts designed to assess the safety, tolerability, PK, and preliminary efficacy of PU-H71 in subjects with PMF, Post-PV MF, Post-ET MF, taking stable…
- Conditions
- Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (Post-PV MF), Post-Essential Thrombocythemia Myelofibrosis (Post-ET MF)
- Trial name
- NCT03935555
- Testing
- PU-H71
- Where
- 3 sites in United States
- Volunteers
- 11 people
- Sponsor
- Samus Therapeutics, Inc.
Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis
Momelotinib Versus Ruxolitinib in Subjects With Myelofibrosis
This study is to determine the efficacy of momelotinib (MMB) versus ruxolitinib (RUX) in participants with primary myelofibrosis (PMF) or post-polycythemia vera or post-essential thrombocythemia myelofibrosis (post-PV/ET MF) who…
- Conditions
- Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, Post-Essential Thrombocythemia Myelofibrosis
- Trial name
- Simplify 1 (NCT01969838)
- Testing
- Momelotinib, Ruxolitinib
- Where
- 114 sites in United States, Australia and 20 more
- Volunteers
- 432 people
- Sponsor
- Sierra Oncology LLC - a GSK company
Primary Myelofibrosis, Post-Polycythemia Vera
An Efficacy and Safety Study of Fedratinib Compared to Best Available Therapy in Subjects With DIPSS-intermediate or High-risk Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis, or Post-essential Thrombocythemia Myelofibrosis and Previously Treated With Ruxolitinib
A Phase 3, multicenter, open-label, randomized study to evaluate the efficacy and safety of fedratinib compared to best available therapy (BAT) in subjects with DIPSS (Dynamic International Prognostic Scoring System)-intermediate…
- Conditions
- Primary Myelofibrosis, Post-Polycythemia Vera, Myelofibrosis
- Trial name
- FREEDOM2 (NCT03952039)
- Testing
- FEDRATINIB, Best Available Therapy (BAT)
- Where
- 107 sites in Australia, Austria and 14 more
- Volunteers
- 202 people
- Sponsor
- Celgene
Primary Myelofibrosis (PMF), Post-polycythemia Vera (Post-PV)
Efficacy of Momelotinib Versus Best Available Therapy in Anemic or Thrombocytopenic Subjects With Primary Myelofibrosis (MF), Post-polycythemia Vera MF, or Post-essential Thrombocythemia MF
This study is to determine the efficacy of momelotinib (MMB) versus best available therapy (BAT) in anemic or thrombocytopenic adults with primary myelofibrosis (PMF), or post-polycythemia vera or post-essential thrombocythemia…
- Conditions
- Primary Myelofibrosis (PMF), Post-polycythemia Vera (Post-PV), Post-essential Thrombocythemia Myelofibrosis (Post-ET MF)
- Trial name
- Simplify 2 (NCT02101268)
- Testing
- Momelotinib, Best Available Therapy (BAT)
- Where
- 48 sites in United States, Canada and 6 more
- Volunteers
- 156 people
- Sponsor
- Sierra Oncology LLC - a GSK company
Primary Myelofibrosis (MF)
A Clinical Study of Ruxolitinib in Patients With Primary Myelofibrosis (PM), Post-polycythemia Vera (PV) Myelofibrosis, or Post-essential Thrombocythemia (ET) Myelofibrosis
This is an open-label, multicenter clinical study in order to collect and examine data concerning the safety and efficacy of ruxolitinib in patients with Primary Myelofibrosis (MF), Post-Polycythemia Vera (PV) MF, Post-Essential…
- Trial name
- NCT02087059
- Testing
- Ruxolitinib
- Where
- 29 sites in Japan
- Volunteers
- 51 people
- Sponsor
- Novartis Pharmaceuticals
Myelofibrosis, Post-PV MF
Study of Navtemadlin add-on to Ruxolitinib in JAK Inhibitor-Naïve Patients With Myelofibrosis Who Have a Suboptimal Response to Ruxolitinib
This clinical trial is evaluating whether addition of navtemadlin to ruxolitinib treatment will provide more clinical benefit than ruxolitinib alone for patients with Myelofibrosis who have a suboptimal response to ruxolitinib…
- Conditions
- Myelofibrosis, Post-PV MF, Post-ET Myelofibrosis, Primary Myelofibrosis
- Trial name
- POIESIS (NCT06479135)
- Testing
- Navtemadlin, Ruxolitinib
- Where
- 215 sites in United States, Australia and 17 more
- Volunteers
- 600 people
- Sponsor
- Kartos Therapeutics, Inc.
Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis
Safety and Tolerability Study of Oral NS-018 in Patients With Primary Myelofibrosis (MF), Post-polycythemia Vera MF or Post-essential Thrombocythemia MF
The purpose of this study is to determine the safety and tolerability of orally administered NS-018 in patients with Primary Myelofibrosis (PMF), Post-polycythemia Vera Myelofibrosis (post-PV MF), or Post-essential…
- Conditions
- Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, Post-Essential Thrombocythemia Myelofibrosis
- Trial name
- NCT01423851
- Testing
- NS-018
- Where
- 9 sites in United States
- Volunteers
- 77 people
- Sponsor
- NS Pharma, Inc.
Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis
A Prospective, Two-arm, Non-interventional Study of JAKAVI® (Ruxolitinib) in Patients With Myelofibrosis
This was a prospective, two-arm, non-interventional study of JAKAVI® (Ruxolitinib) in patients with myelofibrosis
- Conditions
- Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis, Post-essential Thrombocythemia Myelofibrosis
- Trial name
- JAKoMo (NCT05044026)
- Testing
- Jakavi
- Where
- Germany
- Volunteers
- 1,012 people
- Sponsor
- Novartis Pharmaceuticals
Myelofibrosis, Polycythemia Vera
To Assess the Safety, Tolerability and Efficacy of Itacitinib Immediate Release Tablets in Participants With Primary or Secondary Myelofibrosis Who Have Received Prior Ruxolitinib and/or Fedratinib Monotherapy (LIMBER-213)
This is a 2-part study. In Part 1, participants will be dosed at 2 different dose levels in order to select the RP2D for Part 2 of the study.
- Conditions
- Myelofibrosis, Polycythemia Vera, Thrombocythemia
- Trial name
- NCT04629508
- Testing
- itacitinib
- Where
- 21 sites in United States, Austria and 5 more
- Volunteers
- 4 people
- Sponsor
- Incyte Corporation